Zacks Investment Research upgraded shares of Apellis Pharmaceuticals (NASDAQ:APLS) from a sell rating to a hold rating in a research report report published on Tuesday, June 12th.
According to Zacks, “Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. “
A number of other equities analysts have also recently weighed in on APLS. JPMorgan Chase & Co. upped their price target on Apellis Pharmaceuticals from $31.00 to $35.00 and gave the stock an overweight rating in a report on Friday, March 23rd. B. Riley cut Apellis Pharmaceuticals from a buy rating to a neutral rating and set a $27.00 price target for the company. in a report on Thursday, April 12th. ValuEngine raised Apellis Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, May 2nd. Finally, Cantor Fitzgerald started coverage on Apellis Pharmaceuticals in a report on Wednesday, May 23rd. They set an overweight rating for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $32.40.
Shares of APLS traded up $1.11 during mid-day trading on Tuesday, reaching $24.21. The company had a trading volume of 447,207 shares, compared to its average volume of 248,264. Apellis Pharmaceuticals has a 52-week low of $12.45 and a 52-week high of $32.00. The company has a quick ratio of 22.37, a current ratio of 22.37 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $1.25 billion and a price-to-earnings ratio of -6.55.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Monday, April 30th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.11). equities analysts anticipate that Apellis Pharmaceuticals will post -1.62 EPS for the current fiscal year.
In related news, insider Lukas Scheibler purchased 2,935 shares of the company’s stock in a transaction dated Thursday, May 24th. The stock was acquired at an average cost of $20.37 per share, for a total transaction of $59,785.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.30% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of APLS. Candriam Luxembourg S.C.A. purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $2,539,000. The Manufacturers Life Insurance Company purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $186,000. Bank of New York Mellon Corp purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $416,000. BlackRock Inc. purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $21,096,000. Finally, Vivo Capital LLC purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $31,635,000. Institutional investors and hedge funds own 36.72% of the company’s stock.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.